BiondVax Pharmaceuticals prices ~$8M underwritten public offering

Dec. 16, 2022 9:07 AM ETBiondVax Pharmaceuticals Ltd. (BVXV)IBNBy: Mary Christine Joy, SA News Editor

Medical Science Laboratory with Diverse Multi-Ethnic Team of Microbiology Scientists Have Meeting on Developing Drugs, Medicine, Doing Biotechnology Research. Working on Computers, Analyzing Samples

gorodenkoff/iStock via Getty Images

  • Immunotherapeutic products company BiondVax Pharmaceuticals (NASDAQ:BVXV) priced an ~$8M underwritten public offering.
  • The offering consists of 1.6M units and pre-funded units, with each unit consisting of one American Depositary Share and two warrants, each to purchase one ADS. Each

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.